References

1. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. *Eur Respir J* 2020;55:2000607.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497–506.
3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese center for disease control and prevention. *JAMA* [online ahead of print] 24 Feb 2020; DOI: 10.1001/jama.2020.2648.
4. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severity: a multicenter study of clinical features. *Am J Respir Crit Care Med* 2020;201:1380–1388.
5. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. *Nat Med* 2012;18:716–725.
6. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Geneva: World Health Organization; 2020 [accessed 2020 Apr 29]. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
7. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. *Eur Respir J* 2020;55:2001009.
8. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al.; NHLBI Severe Asthma Research Program-3 Investigators. COVID-19-related species in sputum cells in asthma: relationship to demographic features and corticosteroids. *Am J Respir Crit Care Med* 2020;202:83–90.
9. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Science* 2020;368:1058323.
10. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al.; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *Eur Respir J* 2020;55:2000547.
11. Leung JM, Yang CX, Tam A, Shaipanich T, Hackett TL, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. *Eur Respir J* 2020;55:2000688.
12. Brake SJ, Barnsley K, Lu W, McAlinden KD, Eapen MS, Sohal SS. Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19). *J Clin Med* 2020;9:841.
13. Cai G, Bossé Y, Xiao F, Kheradmand F, Amos CI. Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. *Am J Respir Crit Care Med* [online ahead of print] 24 Apr 2020; DOI: 10.1164/rccm.202003-0693LE.
14. Seys LJM, Widagdo W, Verhamme FM, Kleijnjan A, Janssens W, Joos GF, et al. DPP4, the Middle East respiratory syndrome coronavirus receptor, is upregulated in lungs of smokers and chronic obstructive pulmonary disease patients. *Clin Infect Dis* 2018;66:45–53.
15. Seys LJ, Verhamme FM, Schinwald A, Hammad H, Cunodosamy DM, Bantsimba-Malanda C, et al. Role of B cell-activating factor in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2015;192:706–718.

Copyright © 2020 by the American Thoracic Society

© Personalized Blood Pressure Targets in Shock: What If Your Normal Blood Pressure Is “Low”? 

The cornerstone of resuscitation of septic shock is volume infusion followed by vaspressors if fluid volume does not restore adequate perfusion (1). Surviving Sepsis Campaign guidelines recommend an initial target mean arterial pressure (MAP) of 65 mm Hg (1), subsequently adjusted. The target MAP and the relative proportions of use of volume versus vasopressors varies widely (2, 3). But there remains the overarching large question of how to personalize a MAP target in shock (Figure 1).

In patients with hypertension, targeting a higher MAP (80–85 mm Hg) was associated with enhanced renal function but not with lower mortality (4). There are no large studies regarding resuscitation of patients with naturally low blood pressure. Do we resuscitate to 65 mm Hg? Would we use excessive vaspressors and increase organ dysfunction and mortality?

In this issue of the *Journal*, Gershengorn and colleagues (pp. 91–99) determined an inverse relationship between premorbid systolic arterial pressure (SAP) with dose and duration of vaspressors in shock in a single healthcare system cohort (n = 4,689, from 2012 to 2018) (5). Patients were classified as having low blood pressure (SAP < 100 mm Hg), normal blood pressure (SAP 100–139 mm Hg), or high blood pressure (SAP > 140 mm Hg) before shock. The actual MAP during vasopressor infusion was lower in the group with low SAP than in the groups with normal and high SAP (Table 1). We do not know the MAP targets of these groups. Patients with low SAP were treated for longer with higher doses of norepinephrine and had greater ICU length of stay (LOS) and higher mortality. There was no association of premorbid blood pressure and duration of vaspressors with renal replacement therapy (RRT); one might have expected greater duration of RRT if renal function had worsened because of overuse of vaspressors.

The results were robust and consistent across subgroups. These authors tested a very relevant clinical question and used strong analytic methods, and the study’s implications are important. The study was of a large, single healthcare system cohort, limiting the interpretation of generalizability and causality. It would have been insightful to examine cardiovascular outcomes such as arrhythmias (especially atrial fibrillation), stroke (new-onset atrial fibrillation was associated with the higher MAP target group in Asfar and colleagues [6], and new-onset atrial fibrillation is associated with stroke in septic shock [7]), and acute myocardial infarction. These data would further strengthen the argument that the higher dose and
greater duration of vasopressors are harmful and would suggest additional mechanisms for the association between increased vasopressor duration and increased mortality.

Gershengorn and colleagues (5) found that the maximal dose of norepinephrine varied inversely by SAP group, the low-SAP group having a higher median norepinephrine dose. Thus, patients with low premorbid blood pressure had a higher median norepinephrine dose for longer, presumably yielding a greater area under the curve (my assumption) that would increase the risks of norepinephrine-associated serious adverse events.

The duration of vasopressors is not only determined by the target MAP but is also guided by peripheral perfusion, mentation, urine output, and lactate. This study did not have such data. What is the relationship between the duration of vasopressor support and mentation (e.g., Glasgow Coma Score), normalization of urine output, and lactate? Is there still a relationship of premorbid blood pressure and duration of vasopressor use if one controls for effects of vasopressors on these measures of perfusion?

Why would a premorbid blood pressure be associated with increased ICU LOS and higher mortality? Perhaps the higher dose and duration of vasopressors caused serious adverse effects that increased ICU LOS and mortality. Another explanation is that low premorbid blood pressure itself somehow increased ICU LOS and mortality.

Having a low blood pressure is surprisingly common, occurring in nearly half of a cohort having 24-hour blood pressure monitoring (8); only 5% of Gershengorn’s patients had low premorbid SAP, and they were younger and had more heart failure, liver disease, and renal failure. Having a low nonshock blood pressure is also associated with increased risks of depression (9, 10), cognitive dysfunction (11), Alzheimer’s disease (12), cardiovascular events (13), and increased mortality in chronic kidney disease (14). Although adverse effects of excessive vasopressors are the more likely the potential cause of the association of low premorbid blood pressure with shock mortality, the above studies suggest low premorbid blood pressure as a causal contribution, a tenable and testable hypothesis.

There was no association of premorbid blood pressure and higher doses and/or greater duration of norepinephrine with organ dysfunction (sepsis organ failure score), an important negative result. However, there are statistical concerns with how to evaluate continuous data (e.g., sepsis organ failure) in the critically ill because of informative censoring due to early deaths. Harhay and colleagues (15) used joint longitudinal modeling in the VASST (Vasopressin and Septic Shock Trial) cohort to illustrate an improved analytic technique for adjusting informative censoring by deaths in critical-care studies (5).

Low premorbid SAP was associated with more use of vasopressors and greater ICU LOS. ICU duration is composed of the
duration of vasopressor use plus the remaining duration (for ventilator and/or RRT use and weaning). The medians of vasopressor duration and ICU LOS of the three SAP groups differed directly; ICU LOS minus vasopressor duration was 3.7 days for low SAP, 4.2 days for normal SAP, and 4.8 days for high SAP. Other non–vasopressor–related reasons contributed about 1 day more in the high-SAP group than in low-SAP group.

This study of low premorbid blood pressure complements Asfar and colleagues’ (4) evaluation of prior hypertension. Asfar and colleagues (4) found that targeting a higher blood pressure in patients with hypertension decreased need for RRT; Gershengorn and colleagues (5) did not find that greater vasopressor duration was associated with more RRT.

In conclusion, patients with low premorbid blood pressure receive higher doses of norepinephrine for longer and have longer ICU stays and higher mortality but have neither a greater need for RRT nor more organ dysfunction. A randomized trial is needed to define the optimal target MAP in individuals with low blood pressure. For now, I recommend that clinicians personalize their blood pressure target on the basis of premorbid low blood pressure. For now, I recommend that clinicians personalize their blood pressure target on the basis of premorbid low blood pressure (16); if low, consider a lower target MAP than the commonly recommended 65 mm Hg. Conversely, if there is premorbid hypertension, then use a higher MAP target (80–85 mm Hg).

Table 1. Median MAPs during Vasopressor Infusion and Literature Target MAPs in the Low-, Normal- and High-SAP Groups

| Blood Pressure Group | Median MAPs during Vasopressor Infusion (mm Hg) (P < 0.001) | Literature-recommended Target MAP (mm Hg) |
|----------------------|-------------------------------------------------------------|------------------------------------------|
| Low SAP (<100 mm Hg) | 63–71                                                       | NA                                       |
| Normal SAP (110–139 mm Hg) | 68–72                                                     | 65 (1)                                   |
| High SAP (≥140 mm Hg) | 64–74                                                       | 80–85 (4)                                 |

Definition of abbreviations: MAP = mean arterial pressure; NA = not applicable; SAP = systolic arterial pressure.

References

1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock. 2016. Crit Care Med 2017; 45:486–552.

2. Russell JA. Is there a good MAP for septic shock? N Engl J Med 2014; 370:1649–1651.

3. Russell JA, Gordon AC, Walley KR. Early may be better: early low-dose norepinephrine in septic shock. Am J Respir Crit Care Med 2019;199:1049–1051.

4. Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, et al.; SEPSIS-PAM Investigators. High versus low blood-pressure target in patients with septic shock. N Engl J Med 2014;370:1583–1588.

5. Gershengorn HB, Stelfox HT, Niven DJ, Wunsch H. Association of premorbid blood pressure with vasopressor infusion duration in patients with shock. Am J Respir Crit Care Med 2020;202:91–99.

6. Asfar P, Teboul JL, Rademaker P. High versus low blood-pressure target in septic shock. N Engl J Med 2014;371:283–284.

7. Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA 2011;306:2248–2254.

8. Owens PE, Lyons SP, O’Brien ET. Arterial hypotension: prevalence of low blood pressure in the general population using ambulatory blood pressure monitoring. J Hum Hypertens 2000;14:243–247.

9. Stroup-Benham CA, Markides KS, Black SA, Goodwin JS. Relationship between low blood pressure and depressive symptomatology in older people. J Am Geriatr Soc 2000;48:250–255.

10. Niu K, Hozawa A, Awata S, Guo H, Kuriyama S, Seki T, et al. Home blood pressure is associated with depressive symptoms in an elderly population aged 70 years and over: a population-based, cross-sectional analysis. Hypertens Res 2008;31:409–416.

11. Duschek S, Hoffmann A, Bier A, Reyes Del Paso GA, Montoro CI. Cerebral blood flow modulations during proactive control in chronic hypertension. Brain Cogn 2012;125:135–141.

12. Kennelly S, Collins O. Walking the cognitive “minefield” between high and low blood pressure. J Alzheimers Dis 2012;32:609–621.

13. Egan BM, Kai B, Wagner CS, Fleming DO, Henderson JH, Chandler AH, et al. Low blood pressure is associated with greater risk for cardiovascular events in treated adults with and without apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich) 2017;19:241–249.

14. Mitka M. Low diastolic blood pressure and chronic kidney disease are associated with increased mortality. JAMA 2013;310:1215–1216.

15. Harhay MO, Gasparini A, Walkey AJ, Weissman GE, Crowther MJ, Ratcliffe SJ, et al. Assessing the course of organ dysfunction using joint longitudinal and time-to-event modeling in the Vasopressin and Septic Shock Trial. Crit Care Explor [online ahead of print] 29 Apr 2020; DOI: 10.1097/CCE.000000000000104.

16. Asfar P, Rademaker P, Ostermann M. MAP of 65: target of the past? Intensive Care Med 2018;44:1551–1552.